



October 26, 2017

ZiOPHARM Oncology to Host Third-Quarter 2017 Financial Results and Corporate Update Conference Call on November 6, 2017 at 4:30 p.m. ET

BOSTON, Oct. 26, 2017 (GLOBE NEWSWIRE) -- ZiOPHARM Oncology, Inc. (Nasdaq:ZiOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that it will host a conference call and webcast slide presentation on Monday, November 6, 2017 at 4:30 p.m. ET to provide a corporate update and discuss financial results for the third quarter ended September 30, 2017.

The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international). The passcode for the conference call is 8769629. To access the slides and live webcast or the subsequent archived recording, visit the "Investors & Media" section of the ZiOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company's website for two weeks.

About ZiOPHARM Oncology, Inc.:

ZiOPHARM Oncology is a Boston-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Contact:

David Connolly
ZiOPHARM Oncology
617-502-1881
dconnolly@ziopharm.com

or

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com